SC 58125

Drug Profile

SC 58125

Latest Information Update: 26 Jan 2015

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Nonsteroidal anti-inflammatories
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
  • 18 Mar 1999 A study has been added to the pharmacodynamics section
  • 23 Jun 1997 Preclinical development for Colorectal cancer (Prevention)/Chemoprevention in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top